CDK7 Gene Editing    

CDK7 (cyclin-dependent kinase 7) is a member of the cyclin-dependent protein kinase family of serine/threonine kinases that are severely involved in the regulation of transitions between different cell cycle phases. CDK7 is thought to be a direct link between transcriptional regulation and the cell cycle.

CDK7 forms a CDK-activated kinase (CAK) complex with cyclin H and MAT1, and then phosphorylates the T-loop of CDKs in the activated segment, thereby activating CDKs to control the eukaryotic cell cycle. Cyclin H levels and CDK7 activity are unchanged throughout the cell cycle, unlike other CDKs. In addition, CDK7 is also an important component of the transcription factor TFIIH and is capable of phosphorylating the largest subunit of Pol II, the C-terminal domain (CTD), thereby playing an important role in regulating mRNA synthesis at the initial stage and DNA repair (Figure 1).

Figure 1: The functions of CDK7

Due to the important regulatory role of CDK7 in cell division cycle and transcription, CDK7 has also become a target for small molecule inhibitors and is expected to be used for the treatment of cancer and inflammation. The current challenge is to identify relevant targets for CDK7 at each step of the transcription cycle and to understand how high dependence on an important CDK in cancer occurs and how it can be used therapeutically.

CDK7 Gene Editing Service

As one of the global leading biotechnological companies specializing in gene editing, CRISPR/Cas9 Platform^CB is dedicated to providing comprehensive CRISPR/Cas9 gene editing services and products to a wide range of genomics researchers. Based on our platform, we can help you effectively control target genes deleted, inserted or point mutated in cells or animals via CRISPR/Cas9 technology.

• CDK7 Gene Editing Cell Line Generation

We have successfully implemented CDK7 CRISPR/Cas9 gene edited in both easy-to-transfect cell lines and hard-to-transfect cells. With deep gene editing knowledge and extensive experience in experimental operation and data processing, we will offer you full-length custom CDK7 gene editing service from strategy design to final stable cells. Our CDK7 gene editing cell line generation services include:

✧ gRNA design and synthesis
✧ Transfect the cell lines you're interested
✧ Select the high expression cells and sort monoclonal cell
✧ Validate the knockout/knockin/point mutation of CDK7 by PCR and sequencing
✧ Produce cryogenic preserved vials of stable cells and a final report

Typically, we develop CRISPR-mediated gene editing cell lines including HEK239T, Hela, HepG2, U87, but we can use other cell lines according to your requirements.

Other host cell lines available: Ba/F3, CHO, MDA-MB-453, MDA-MB-231NIH3T3, T47D, Neuro2a, MCF7, RKO, K562, RAW264.7, etc.

• CDK7 Gene Editing Animal Model Generation

CRISPR/Cas9 Platform^CB also has extensive experience in incorporating CRISPR system into animal models, which have been fully recognized by our clients. Tell us your needs, we will provide a one-stop-shop CDK7 CRISPR/Cas9 gene editing animal service and guarantee at least 2 founders or 3 F1 animals with shorter turnaround time and lower price. Our CDK7 gene editing animal model generation services include:

➢ CDK7 gene conventional knockout animals
➢ CDK7 gene conditional knockout animals
➢ CDK7 point mutation animals
➢ CDK7 knockin animals

Alternative species: mouse, rat, rabbit, zebrafish, C. elegans, etc.

With many years of experience on gene editing, CRISPR/Cas9 Platform^CB is devoted to providing the best gene editing services and products for academic research, biotech research and pharmaceutical drug discovery with excellent quality management and quality assurance capacity. To accelerate the achievement of your research goals, our gene editing expert team provides you with custom CRISPR/Cas9 services for any specific gene to help you solve problems encountered during your research. There is no doubt that CRISPR/Cas9 Platform^CB will be your best partner to support your research.

Related Products at CRISPR/Cas9 Platform^CB